These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 36983317)
1. Safe and Successful Surgical Outcome in Persons with Hemophilia A with and without Inhibitors Treated with Emicizumab: A Large, Single Center, Real-World Experience. Castaman G; Linari S; Pieri L; Carulli C; Prosperi P; Tonelli P; Demartis F; Fjerza R; Attanasio M; Coppo M; Salvianti F J Clin Med; 2023 Mar; 12(6):. PubMed ID: 36983317 [TBL] [Abstract][Full Text] [Related]
2. Management of people with haemophilia A undergoing surgery while receiving emicizumab prophylaxis: Real-world experience from a large comprehensive treatment centre in the US. Lewandowska M; Randall N; Bakeer N; Maahs J; Sagar J; Greist A; Shapiro AD Haemophilia; 2021 Jan; 27(1):90-99. PubMed ID: 33245841 [TBL] [Abstract][Full Text] [Related]
3. Concomitant Use of rFVIIa and Emicizumab in People with Hemophilia A with Inhibitors: Current Perspectives and Emerging Clinical Evidence. Linari S; Castaman G Ther Clin Risk Manag; 2020; 16():461-469. PubMed ID: 32547043 [TBL] [Abstract][Full Text] [Related]
4. Management of surgery in persons with hemophilia A receiving emicizumab prophylaxis: data from a national hemophilia treatment center. Cohen O; Levy-Mendelovich S; Budnik I; Ludan N; Lyskov SK; Livnat T; Avishai E; Efros O; Lubetsky A; Lalezari S; Misgav M; Brutman-Barazani T; Kenet G; Barg AA Res Pract Thromb Haemost; 2023 Aug; 7(6):102178. PubMed ID: 37876894 [TBL] [Abstract][Full Text] [Related]
5. Surgical Experience from the STASEY Study of Emicizumab Prophylaxis in People with Hemophilia A with Factor VIII Inhibitors. Castaman G; Peyvandi F; Kremer Hovinga JA; Schutgens REG; Robson S; Moreno K; Jiménez-Yuste V TH Open; 2024 Jan; 8(1):e42-e54. PubMed ID: 38222041 [No Abstract] [Full Text] [Related]
6. Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies. Kruse-Jarres R; Peyvandi F; Oldenburg J; Chang T; Chebon S; Doral MY; Croteau SE; Lambert T; Kempton CL; Pipe SW; Ko RH; Trzaskoma B; Dhalluin C; Bienz NS; Niggli M; Lehle M; Paz-Priel I; Young G; Jiménez-Yuste V Blood Adv; 2022 Dec; 6(24):6140-6150. PubMed ID: 35939785 [TBL] [Abstract][Full Text] [Related]
7. Management and Outcomes of Invasive Procedures in Individuals with Hemophilia A on Emicizumab Prophylaxis: A Single Center Experience. Rener K; Anžej Doma S; Fink M; Podgornik H; Preložnik Zupan I Hematol Rep; 2023 Nov; 15(4):597-607. PubMed ID: 37987318 [TBL] [Abstract][Full Text] [Related]
8. Evaluating the safety of emicizumab in patients with hemophilia A. Langer AL; Etra A; Aledort L Expert Opin Drug Saf; 2018 Dec; 17(12):1233-1237. PubMed ID: 30462521 [TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of major knee surgery with recombinant activated factor VII in hemophilia patients with high titer inhibitors and advanced knee arthropathy: exploratory results via literature-based modeling. Ballal RD; Botteman MF; Foley I; Stephens JM; Wilke CT; Joshi AV Curr Med Res Opin; 2008 Mar; 24(3):753-68. PubMed ID: 18234151 [TBL] [Abstract][Full Text] [Related]
10. Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations. Yada K; Nogami K J Blood Med; 2019; 10():171-181. PubMed ID: 31308776 [TBL] [Abstract][Full Text] [Related]
11. Predicted coagulation potential using an in vitro simulated model of emicizumab prophylaxis and immune tolerance induction therapy in hemophilia A patients with inhibitor. Nakajima Y; Tonegawa H; Noguchi-Sasaki M; Nogami K Int J Hematol; 2021 Jun; 113(6):789-796. PubMed ID: 33635530 [TBL] [Abstract][Full Text] [Related]
12. Economic impact model of delayed inhibitor development in patients with hemophilia a receiving emicizumab for the prevention of bleeding events. Patel AM; Corman SL; Chaplin S; Raimundo K; Sidonio RF J Med Econ; 2019 Dec; 22(12):1328-1337. PubMed ID: 31530050 [No Abstract] [Full Text] [Related]
13. Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors. Hassan E; Jonathan L; Jayashree M Haemophilia; 2021 Nov; 27(6):e698-e703. PubMed ID: 34628693 [TBL] [Abstract][Full Text] [Related]
14. Synergistic Effect of Bypassing Agents and Sequence Identical Analogue of Emicizumab and Fibrin Clot Structure in the In Vitro Model of Hemophilia A. Zong Y; Antovic A; Soutari NMH; Antovic J; Pruner I TH Open; 2020 Apr; 4(2):e94-e103. PubMed ID: 32704613 [TBL] [Abstract][Full Text] [Related]
15. A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab. Batt K; Schultz BG; Caicedo J; Hollenbeak CS; Agrawal N; Chatterjee S; Bullano M Curr Med Res Opin; 2022 Oct; 38(10):1685-1693. PubMed ID: 35880468 [TBL] [Abstract][Full Text] [Related]
16. Bispecific Antibodies and Advances in Non-Gene Therapy Options in Hemophilia. Shima M Res Pract Thromb Haemost; 2020 May; 4(4):446-454. PubMed ID: 32548546 [TBL] [Abstract][Full Text] [Related]
17. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A. Gelbenegger G; Schoergenhofer C; Knoebl P; Jilma B Thromb Haemost; 2020 Oct; 120(10):1357-1370. PubMed ID: 32717759 [TBL] [Abstract][Full Text] [Related]
18. Effectiveness of emicizumab in preventing bleeding events in severe and moderate hemophilia A: A single-center experience in Bangladesh. Tory SS; Ghosh S; Nazneen H; Farhad N; Islam S; Hasan MJ; Biswas AR EJHaem; 2024 Feb; 5(1):39-46. PubMed ID: 38406515 [TBL] [Abstract][Full Text] [Related]
19. Early real-world experience with emicizumab and concomitant factor VIII replacement products in adult males with Hemophilia A without inhibitors. Cafuir L; Estrin A; Chen E; Hinds D; Prince P; Thorburn J; Mead H; Kempton CL J Med Econ; 2022; 25(1):984-992. PubMed ID: 35848992 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and Pharmacodynamics of Emicizumab in Persons with Hemophilia A with Factor VIII Inhibitors: HAVEN 1 Study. Schmitt C; Adamkewicz JI; Xu J; Petry C; Catalani O; Young G; Negrier C; Callaghan MU; Levy GG Thromb Haemost; 2021 Mar; 121(3):351-360. PubMed ID: 33086400 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]